{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:50:31Z","timestamp":1790383831221,"version":"4.1.0"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100008052","name":"Fundaci\u00f3n Alfonso Mart\u00edn Escudero","doi-asserted-by":"crossref","award":["0000"],"award-info":[{"award-number":["0000"]}],"id":[{"id":"10.13039\/100008052","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007155","name":"Medical Research Council","doi-asserted-by":"publisher","award":["APP2007007"],"award-info":[{"award-number":["APP2007007"]}],"id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007155","name":"Medical Research Council","doi-asserted-by":"publisher","award":["APP2009736"],"award-info":[{"award-number":["APP2009736"]}],"id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["CM23\/00259"],"award-info":[{"award-number":["CM23\/00259"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["JR23\/00074"],"award-info":[{"award-number":["JR23\/00074"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","award":["0000"],"award-info":[{"award-number":["0000"]}],"id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,12,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The efficacy, safety, and population pharmacokinetics of a single 1,500 mg dose of dalbavancin as a sequencing treatment for Gram-positive chronic prosthetic joint infections (CPJIs) have not been described. We present an observational, retrospective study conducted in two Spanish hospitals including patients with CPJI caused by Gram-positive bacteria susceptible to dalbavancin managed with two-stage exchange, antibiotic-loaded spacers, and a single 1,500 mg dose of dalbavancin. Follow-up visits included measurement of dalbavancin plasma concentrations. Negative intraoperative cultures at second-stage surgery defined microbiological cure. Population pharmacokinetics and Monte Carlo dosing simulations were used to evaluate whether this dose provided a therapeutic antibiotic exposure defined as the ratio between the area under the unbound concentration curve and the bacteria minimum inhibitory concentration (\u0192AUC\n                      <jats:sub>0-24h<\/jats:sub>\n                      \/MIC) \u2265 50 for the entire treatment period. Twenty patients were included, with CPJI mostly caused by coagulase-negative staphylococci (71%). After 11.5 days of intravenous antibiotic therapy (vancomycin, 75%), patients received 1,500 mg of dalbavancin without adverse events. Microbiological cure was 94.7% (median follow-up, 693 days). Dosing simulations suggest that a single 1,500 mg dose of dalbavancin is sufficient for maintaining \u0192AUC\n                      <jats:sub>0-24h<\/jats:sub>\n                      \/MIC \u2265 50 for MIC \u2264 0.25 mg\/L for 3\u20134 weeks after administration. A single 1,500 mg dose of dalbavancin combined with antibiotic-loaded spacers may be an effective and safe sequencing treatment for CPJI and provide 3\u20134 weeks of therapeutic exposure for susceptible microorganisms. Considering dalbavancin\u2019s unique pharmacokinetics, this approach may be considered in the clinical management of CPJI.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00773-25","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T16:42:56Z","timestamp":1760719376000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-1766","authenticated-orcid":true,"given":"Eva","family":"Benavent","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/021018s57","id-type":"ROR","asserted-by":"publisher"}],"name":"Infectious Diseases Department, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, L\u2019Hospitalet de Llobregat","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Lora-Tamayo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00qyh5r35","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Imas12","place":["Madrid, Spain"]},{"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}],"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ulldemolins","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/021018s57","id-type":"ROR","asserted-by":"publisher"}],"name":"Infectious Diseases Department, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, L\u2019Hospitalet de Llobregat","place":["Barcelona, Spain"]},{"id":[{"id":"https:\/\/ror.org\/00rqy9422","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland","place":["Brisbane, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Pons-Oltra","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/021018s57","id-type":"ROR","asserted-by":"publisher"}],"name":"Infectious Diseases Department, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, L\u2019Hospitalet de Llobregat","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1232-5761","authenticated-orcid":true,"given":"Matthieu","family":"Gregoire","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rqy9422","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland","place":["Brisbane, Australia"]},{"id":[{"id":"https:\/\/ror.org\/03gnr7b55","id-type":"ROR","asserted-by":"publisher"}],"name":"Nantes Universit\u00e9, CHU Nantes, Service de Pharmacologie Clinique","place":["Nantes, France"]},{"name":"Nantes Universit\u00e9, CHU Nantes, Cibles et M\u00e9dicaments des Infections et de l\u2019Immunit\u00e9, IICiMed","place":["Nantes, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Manche\u00f1o-Losa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00qyh5r35","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Imas12","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-6278","authenticated-orcid":true,"given":"Pilar","family":"Hern\u00e1ndez-Jim\u00e9nez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00qyh5r35","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Imas12","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9582-3162","authenticated-orcid":true,"given":"M. \u00c1ngeles","family":"Mel\u00e9ndez-Carmona","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00qyh5r35","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Microbiology, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Biom\u00e9dica \"imas12\" Hospital 12 de Octubre","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Casals","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/021018s57","id-type":"ROR","asserted-by":"publisher"}],"name":"Orthopedic Surgery Department, Hospital Universitari de Bellvitge, IDIBELL, L\u2019Hospitalet de Llobregat, Universitat de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rqy9422","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland","place":["Brisbane, Australia"]},{"name":"Herston Infectious Diseases Institute (HeIDI), Metro North Health","place":["Brisbane, Australia"]},{"id":[{"id":"https:\/\/ror.org\/05p52kj31","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, Royal Brisbane and Women's Hospital","place":["Brisbane, Australia"]},{"id":[{"id":"https:\/\/ror.org\/05p52kj31","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital","place":["Brisbane, Australia"]},{"id":[{"id":"https:\/\/ror.org\/051escj72","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Anesthesia, Critical Care and Emergency and Pain Medicine, Nimes University Hospital, University of Montpellier","place":["Nimes, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Rigo-Bonnin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/021018s57","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Clinical Laboratory, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5776-8422","authenticated-orcid":true,"given":"Oscar","family":"Murillo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/021018s57","id-type":"ROR","asserted-by":"publisher"}],"name":"Infectious Diseases Department, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, L\u2019Hospitalet de Llobregat","place":["Barcelona, Spain"]},{"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}],"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13040293"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp177"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz202"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S29025"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/17453670902805064"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.05.004"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-008-0509-3"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01088-w"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac120"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.11.008"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106945"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.103B1.BJJ-2020-1381.R1"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2018.02.078"},{"key":"e_1_3_4_15_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2025 MIC and Zone Diameter Distributions and ECOFFs. Available from: www.eucast.org"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00576-06"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.01.017"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107498"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-010-9238-5"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_3_4_23_2","unstructured":"European Medicines Agency. 2025. European medicines agency. xydalba. symmary of product information. Available from: http:\/\/www.ema.europa\/eu"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac131"},{"key":"e_1_3_4_25_2","first-page":"1","volume-title":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products","author":"European Medicines Agency (EMA)","year":"2016","unstructured":"European Medicines Agency (EMA). 2016. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products, p 1\u201317. Committee for Medicinal Products for Human Use (CHMP)."},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01264-06"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01717-15"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.004"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02307-18"},{"key":"e_1_3_4_30_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2025 European Committee on Antimicrobial Susceptibility Testing (EUCAST). clinical breakpoints and dosing. Available from: https:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad069"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2019.10.001"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis803"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1185602"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac178"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2025.03.001"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1968-1971.2003"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.2165\/11539220-000000000-00000"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200948020-00002"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04550-14"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0010-4809(72)90051-1"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.695"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad331"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106960"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00773-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00773-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T14:04:44Z","timestamp":1765375484000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00773-25"}},"subtitle":[],"editor":[{"given":"Sarah","family":"Doernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,10]]}},"alternative-id":["10.1128\/aac.00773-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.00773-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"2025-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00773-25"}}